TY - JOUR AU - O, Balaji AU - D, Amita AU - Rt, Sereen AU - Ap, Navin PY - 2017/06/01 Y2 - 2024/03/29 TI - HAVING A GO AT SPINAL MUSCULAR ATROPHY WITH SPINRAZA JF - Asian Journal of Pharmaceutical and Clinical Research JA - Asian J Pharm Clin Res VL - 10 IS - 6 SE - Review Article(s) DO - 10.22159/ajpcr.2017.v10i6.17502 UR - https://journals.innovareacademics.in/index.php/ajpcr/article/view/17502 SP - 16-18 AB - <p>Spinal muscular atrophy (SMA), a neurological condition which is genetically mediated is the second most common infantile disease causing morbidity and mortality next to cystic fibrosis. It is of five different types with each type having different severity outcomes. For almost three decades, only supportive measures were advocated in the treatment of SMA. Recently, Biogen's Spinraza came out as the first disease modifying therapy to treat infantile as well as adult SMA. This review throws light on the pharmacological aspects of the drug; its approval by Food and Drug Administration and various completed clinical trials as well ongoing clinical trials.</p> ER -